Bruder-Nascimento Thiago, Butler Benjamin R, Herren David J, Brands Michael W, Bence Kendra K, Belin de Chantemèle Eric J
Department of Physiology, Medical College of Georgia at Georgia Regents University, Augusta, GA, United States.
Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Pharmacol Res. 2015 Dec;102:235-44. doi: 10.1016/j.phrs.2015.10.012. Epub 2015 Oct 30.
Protein tyrosine phosphatase 1b (Ptp1b), which represses leptin signaling, is a promising therapeutic target for obesity. Genome wide deletion of Ptp1b, increases leptin sensitivity, protects mice from obesity and diabetes, but alters cardiovascular function by increasing blood pressure (BP). Leptin-control of metabolism is centrally mediated and involves proopiomelanocortin (POMC) neurons. Whether these neurons contribute to leptin-mediated increases in BP remain unclear. We hypothesized that increasing leptin signaling in POMC neurons with Ptp1b deletion will sensitize the cardiovascular system to leptin and enhance neurogenic control of BP. We analyzed the cardiovascular phenotype of Ptp1b+/+ and POMC-Ptp1b-/- mice, at baseline and after 7 days of leptin infusion or sympatho-activation with phenylephrine. POMCPtp1b deletion did not alter baseline cardiovascular hemodynamics (BP, heart rate) but reduced BP response to ganglionic blockade and plasma catecholamine levels that suggests a decreased neurogenic control of BP. In contrast, POMC-Ptp1b deletion increased vascular adrenergic reactivity and aortic α-adrenergic receptors expression. Chronic leptin treatment reduced vascular adrenergic reactivity and blunted diastolic and mean BP increases in POMC-Ptp1b-/- mice only. Similarly POMC-Ptp1b-/- mice exhibited a blunted increased in diastolic and mean BP accompanied by a gradual reduction in adrenergic reactivity in response to chronic vascular sympatho-activation with phenylephrine. Together these data rule out our hypothesis but suggest that deletion of Ptp1b in POMC neurons protects from leptin- and sympatho-mediated increases in BP. Vascular adrenergic desensitization appears as a protective mechanism against hypertension, and POMC-Ptp1b as a key therapeutic target for the treatment of metabolic and cardiovascular dysfunctions associated with obesity.
蛋白酪氨酸磷酸酶1b(Ptp1b)可抑制瘦素信号传导,是治疗肥胖症的一个有前景的靶点。在全基因组范围内删除Ptp1b可增加瘦素敏感性,保护小鼠免受肥胖症和糖尿病的影响,但会通过升高血压(BP)改变心血管功能。瘦素对代谢的控制是由中枢介导的,涉及促肾上腺皮质激素原(POMC)神经元。这些神经元是否导致瘦素介导的血压升高仍不清楚。我们假设,通过删除Ptp1b增加POMC神经元中的瘦素信号传导将使心血管系统对瘦素敏感,并增强对血压的神经源性控制。我们分析了Ptp1b+/+和POMC-Ptp1b-/-小鼠在基线时以及瘦素输注7天或用去氧肾上腺素进行交感神经激活后的心血管表型。POMC-Ptp1b基因缺失并未改变基线心血管血流动力学(血压、心率),但降低了对神经节阻滞和血浆儿茶酚胺水平的血压反应,这表明对血压的神经源性控制降低。相反,POMC-Ptp1b基因缺失增加了血管肾上腺素能反应性和主动脉α-肾上腺素能受体表达。慢性瘦素治疗仅降低了POMC-Ptp1b-/-小鼠的血管肾上腺素能反应性,并减弱了舒张压和平均血压的升高。同样,POMC-Ptp1b-/-小鼠在对去氧肾上腺素进行慢性血管交感神经激活时,舒张压和平均血压升高减弱,同时肾上腺素能反应性逐渐降低。这些数据共同排除了我们的假设,但表明POMC神经元中Ptp1b的缺失可防止瘦素和交感神经介导的血压升高。血管肾上腺素能脱敏似乎是一种抗高血压的保护机制,而POMC-Ptp1b是治疗与肥胖相关的代谢和心血管功能障碍的关键治疗靶点。